Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the

Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.

A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.

Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.